Clinical Trials Logo

Midgut Neuroendocrine Tumors clinical trials

View clinical trials related to Midgut Neuroendocrine Tumors.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03667092 Active, not recruiting - Clinical trials for Midgut Neuroendocrine Tumors

Exploration of Molecular Biomarkers for Lu-177 DOTATATE Therapy in Midgut Neuroendocrine Tumor

GENEBIOLuNET
Start date: September 1, 2018
Phase: N/A
Study type: Interventional

Midgut neuroendocrine tumours present an increasing incidence and poor survival at 5 years with limited therapeutic options for metastatic, non-operable cases. Lu-177 Dotatate, targeting somatostatin receptors, is an internal vectorized radiotherapy using Lu-177, an ideal radionuclide for peptide radionuclide therapy. In NETTER-1 phase III randomized clinical trial, Lu-177 Dotatate proved its superiority in increasing progression free survival for midgut neuroendocrine tumors. This study hypothesize that finding biomarkers of individual radio sensitivity for this type of internal vectorized therapy would allow treatment personalization. The protocol aim at studying transcript variations induced by this therapy.